Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

IP finance gap risks startup exodus, EUIPO warns
Europe
IP finance gap risks startup exodus, EUIPO warns
New report finds that just 13% of IP-owning firms have sought financing through their assets, with billions in potential funding left untapped, as structural barriers persist.   13 April 2026
LSPN Awards USA: Meet the judges
Americas
LSPN Awards USA: Meet the judges
The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.   10 April 2026
Faegre Drinker boosts FDA regulatory practice with two senior hires
Careers
Faegre Drinker boosts FDA regulatory practice with two senior hires
The firm has added two partners to its government and regulatory team, bringing expertise in FDA matters, product approvals, and regulatory risk.   9 April 2026
Biotech
Gilead to pay up to $5bn for antibody-drug conjugates push
The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.   8 April 2026
Biotech
Closing the women's health gap offers ‘benefits for all’
On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.   7 April 2026
Europe
European patent offices raise fees
Two of Europe’s most important IP offices have implemented fee increases this month, with some long-standing UK charges, dating back to the late 1990s, finally seeing a rise.   2 April 2026
Europe
UPC refuses early knockout in Illumina–Element dispute
A Lisbon judge rejects a bid to strike out the case over a drafting issue, offering insight into the court’s high bar for early dismissal.   2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.   1 April 2026
Americas
CRISPR priority feud ends at USPTO as board reaches decision
A long-running patent clash over gene editing returns to a fundamental question, as a US court takes another look at the evidence.   30 March 2026
Biotech
Novartis bets $2bn on biologics as Xolair patents fade
The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.   27 March 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.